CARA THERAPEUTICS INC

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

03 авг 2022 06:00:01 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

01 авг 2022 15:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

30 июн 2022 06:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at Upcoming Investor Conferences

17 май 2022 06:00:02 Источник Nasdaq GlobeNewswire

Cara Therapeutics Reports First Quarter 2022 Financial Results

09 май 2022 15:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at May Investor Conferences

03 май 2022 15:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

29 апр 2022 06:00:00 Источник Nasdaq GlobeNewswire

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

28 апр 2022 00:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

05 апр 2022 06:00:01 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

04 апр 2022 15:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

28 мар 2022 06:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

08 мар 2022 15:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

01 мар 2022 15:01:00 Источник Nasdaq GlobeNewswire

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

25 фев 2022 06:15:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

22 фев 2022 15:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

18 фев 2022 06:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

10 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 янв 2022 15:01:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

20 дек 2021 06:00:00 Источник Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

18 ноя 2021 07:30:00 Источник Nasdaq GlobeNewswire